Item 5.07. Submission of Matters to a Vote of Security Holders.
On April 14, 2023, Synaptogenix, Inc. (the "Company") held a special meeting of
its stockholders (the "Special Meeting"). At the Special Meeting, the holders of
2,923,975 shares of the Company's common stock, par value $0.0001 per share (the
"Common Stock"), or approximately 40.23% of the outstanding shares of Common
Stock, were represented at the meeting or by proxy and, therefore, a quorum was
present. At the Special Meeting, the stockholders considered one proposal, which
is described briefly below and in more detail in the Definitive Proxy Statement
on Schedule 14A for the Special Meeting filed by the Company with the U.S.
Securities and Exchange Commission on March 27, 2023. The final voting results
for the proposal are set forth below.
Proposal - Authorization of Issuance of Common Stock
The Company's stockholders voted to authorize, for purposes of complying with
Nasdaq Listing Rule 5635(d), of the issuance of shares of Common Stock
underlying shares of convertible preferred stock and warrants issued by the
Company pursuant to the terms of that certain Securities Purchase Agreement,
dated November 17, 2022, by and among the Company and the investors named
therein, in an amount equal to or in excess of 20% of Common Stock outstanding
before the issuance of such convertible preferred stock and warrants (including
the amortization payments made to the holders of convertible preferred stock in
the form of issuance of common stock and upon the operation of anti-dilution
provisions contained in such convertible preferred stock and warrants), by the
following votes:
Shares Voted For Shares Voted Against Abstentions
2,077,004 791,292 55,679
© Edgar Online, source Glimpses
SYNAPTOGENIX, INC. 
